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Letter to the Editor
Should we focus on quality or quantity in
meta-analyses?
In an invited commentary (Moritz et al. 2016), the
developers of metacognitive training (MCT) have chal-
lenged the results of the meta-analysis on the efﬁcacy
of MCT on positive symptoms, delusions and data
gathering bias (van Oosterhout et al. 2015). The recom-
mendation of this meta-analysis was not to implement
MCT in routine care at this moment, because of a lack
of evidence.
In their introduction (Moritz et al. 2011) refer to another
meta-analysis by Jiang et al. (2015) quoting signiﬁcant
effects for positive symptoms (as well as for delusions
without the study by van Oosterhout et al. 2014). The
van Oosterhout et al. (2014) study is a negative study,
but it is the largest randomized controlled trial (RCT)
and indeed was rated as the study with the lowest risk
of bias by Jiang et al.; it is not clearwhyonewoulddiscard
the best study to date? The developers could usefully be
referred to the conclusion in the abstract of Jiang et al.:
‘The limited number of RCT trials, the variability of the
method and time of the outcome evaluation, and meth-
odological problems in the trials make it impossible to
come to a conclusion about the effectiveness of MCT for
schizophrenia. More randomized trials that use standar-
dized outcomemeasures, that use intention-to-treat (ITT)
analyses, and that follow-up participants at regular inter-
vals after the intervention are needed to determine
whether or notMCT should become a recommended ad-
junctive treatment for schizophrenia.’ In our opinion this
conclusion is the same as ours.
In their rebuttal the developers apply four headings
with different arguments; these are addressed below.
Studies omitted
Moritz et al. note that some studies were omitted; we
reran our analyses including the appropriate studies.
We added the data of Aghotor et al. (2010); Moritz
et al. (2011) and Gaweda et al. (2015). We found the
data in the meta-analysis of Eichner (2015), a PhD
student of Moritz, who was kind enough to provide
the data via Research Gate. We discarded two non-
randomized studies: an extremely negative study by
Rocha & Queirós (2013) and an extremely positive
study by Erawati et al. (2014).
It is not accurate to say that we omitted the So et al.
(2015) study from our paper because it had not been
published – or accepted for publication – at the point
our meta-analysis was accepted for publication.
However, we have added this study in our reanalysis.
The results of the reanalysis demonstrate that there are
some signiﬁcant effects for positive symptoms (g = 0.32)
and delusions (g = 0.31), but not for data gathering (g =
0.11) if all the studies are considered. However, the
ﬁndings from the high-quality and intention-to-treat
data are similar to our original results with no signiﬁcant
effects ondelusions, positive symptomsordatagathering.
Heterogeneity and moderator analysis
Wechose to conduct someadditionalmoderatoranalyses
with the high-quality studies and not the low-quality
studies as Moritz et al. suggest. Van Oosterhout et al.
(2014) is the largest study with the lowest risk of bias,
but is a negative study. It does not make sense to remove
robust studies from an analysis only to remove
heterogeneity.
MCT+ is not CBT
The authors (Moritz et al. 2011b) wrote in the paper on
MCT+ that ‘Individualized metacognitive therapy
(MCT+) followed group sessions according to the gen-
eral guidelines for CBT (e.g. Fowler et al. 1995).’ As
Fowler is one of the founding fathers of CBT for psych-
osis, this led us to conclude that MCT+ is based on
CBT. In the same paper it is stated: ‘MCT . . . is
grounded on the principles of CBT (Fowler et al.
1995) and basic research on cognitive biases in schizo-
phrenia (for reviews, see Garety & Freeman, 1999;
Freeman et al. 2007), as well as deﬁcits in social cogni-
tion/theory of mind (Frith, 1994; Frith & Corcoran,
1996).’ CBT in psychosis has included work on cogni-
tive biases for over a decade. The main difference
seems to be that MCT is set up like a course targeting
transfer of ‘cold cognitions’, while CBT focuses on per-
sonalizing and experiencing the effects of biases in real
life. In doing so, CBT is rather aimed at modifying ‘hot
cognitions’.
Evolution of MCT
Moritz and colleagues suggested changing the inclu-
sion criteria to patients without severe delusions. We
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have checked the baseline data of the studies on delu-
sions. The three studies with the highest baseline delu-
sion scores were So et al. (2015), Favrod (2014) and
van Oosterhout et al. (2014). Taking these three studies,
the effect size is 0.49, while studies with the lowest de-
lusion scores at baseline (Moritz et al. 2011a,b, 2013; Briki
et al. 2014; Gaweda et al. 2015) have a pooled effect size
of 0.25 on delusions. So the empirical evidence rather
suggests that patients with highest baseline scores of
paranoia in general beneﬁt most from therapy.
In summary, we appreciate the opportunity to air
these differences in opinion; but have to conclude that
the best available evidence suggests that MCT is not
yet at a stage to advocate its routine use. That is to say,
we acknowledge Moritz et al.’s position that MCT is
work in progress and this progress needs to be data dri-
ven. However, including less rigorous evidence into a
meta-analysis may offer a different opinion, but this is




Aghotor J, Pfueller U, Moritz S, Weisbrod M, Roesch-Ely D
(2010). Metacognitive training for patients with
schizophrenia (MCT): feasibility and preliminary evidence
for its efﬁcacy. Journal of Behavior Therapy and Experimental
Psychiatry 41, 207–211.
Briki M, Monnin J, Haffen E, Sechter D, Favrod J, Netillard
C, Vandel P (2014). Metacognitive training for
schizophrenia: a multicentre randomised controlled trial.
Schizophrenia Research 157, 99–106.
Eichner C (2015). Can metacognitive training (MCT) reduce
positive symptoms and delusions in patients with
schizophrenia? A meta-analysis taking into account
important moderators. University of Hamburg: Hamburg.
Erawati E, Keliat BA, Helena N, Hamid A (2014). The
inﬂuence of metacognitive training on delusion severity
and metacognitive ability in schizophrenia. Journal of
Psychiatric and Mental Health Nursing 21, 841–847.
Favrod J, Rexhaj S, Bardy S, Ferrari P, Hayoz C, Moritz S,
Conus P, Bonsack C (2014). Sustained antipsychotic effect of
metacognitive training in psychosis: a randomized controlled
study. European Psychiatry 29, 275–281.
FowlerD,GaretyP,Kuipers E (1995).Cognitive Behaviour Therapy
for Psychosis: Theory and Practice. Wiley, Chichester, UK.
Gaweda L, Krezolek M, Olbrys J, Turska A, Kokoszka A
(2015). Decreasing self-reported cognitive biases and
increasing clinical insight throughmeta-cognitive training in
patientswith chronic schizophrenia. Journal of Behavior Therapy
and Experimental Psychiatry 48, 98–104.
Jiang J, Zhang L, Zhu Z, Li W, Li C (2015). Metacognitive
training for schizophrenia: a systematic review. Shanghai
Archives of Psychiatry 27, 149–157.
Moritz S, Kerstan A, Veckenstedt R, Randjbar S, Vitzthum
F, Schmidt C, Woodward TS (2011a). Further evidence for
the efﬁcacy of a metacognitive group training in
schizophrenia. Behaviour Research and Therapy 49, 151–157.
Moritz S, Veckenstedt R, Randjbar S, Vitzthum F,
Woodward TS (2011b). Antipsychotic treatment beyond
antipsychotics: metacognitive intervention for
schizophrenia patients improves delusional symptoms.
Psychological Medicine 41, 1823–1832.
Moritz S, Veckenstedt R, Bohn F, Hottenrott B, Scheu F,
Randjbar S, Aghotor J, Kother U, Woodward TS, Treszl A,
Andreou C, Pfueller U, Roesch-Ely D (2013).
Complementary group metacognitive training (MCT)
reduces delusional ideation in schizophrenia. Schizophrenia
Research 151, 61–69.
Moritz S, Werner D, Menon M, Balzan RP, Woodward TS
(2016). Jumping to negative conclusions – a case of study-
gathering bias? Psychological Medicine 46, 59–61.
Rocha NB, Queirós C (2013). Metacognitive and social
cognition training (MSCT) in schizophrenia: a preliminary
efﬁcacy study. Schizophrenia Research 150, 64–68.
So SH, Chan AP, Chong CS, Wong MH, Lo WT, Chung DW,
Chan SS (2015). Metacognitive training for
delusions (MCTd): effectiveness on data-gathering and
belief ﬂexibility in a Chinese sample. Frontiers in
Psychology 6, 730.
van Oosterhout B, Krabbendam L, de Boer K, Ferwerda J,
van der Helm M, Stant AD, van der Gaag M (2014).
Metacognitive group training for schizophrenia spectrum
patents with delusions: a randomized controlled trial.
Psychological Medicine 44, 3025–3035.
van Oosterhout B, Smit F, Krabbendam L, Castelein S,
Staring AB, van der Gaag M (2015). Metacognitive training
for schizophrenia spectrum patients: a meta-analysis on
outcome studies. Psychological Medicine. Published online:
20 July 2015. doi:10.1017/s0033291715001105
B . VAN OOSTERHOUT1,*, F . SM IT2,3,4, L . KRABBENDAM5,
S . CASTELE IN6,7, A . B . P. STAR ING8 AND M. VAN DER
GAAG
4,9
1GGzE, De Woenselse Poort, Eindhoven, The Netherlands
2Trimbos Institute (Netherlands Institute of Mental Health
and Addiction), Utrecht, The Netherlands
3Department of Epidemiology and Biostatistics, EMGO
Institute for Health and Care Research, VU University
Medical Centre, Amsterdam, The Netherlands
4Department of Clinical Psychology, EMGO Institute for
Health and Care Research, VU University, Amsterdam, The
Netherlands
5Department of Educational Neuroscience and Research
Institute Learn!,Faculty of Psychology and Education, VU
University, Amsterdam, The Netherlands
6Lentis Psychiatric Institute, Lentis Research, Groningen,
The Netherlands
7University of Groningen, University Medical Center




Downloaded from https:/www.cambridge.org/core. IP address: 145.97.142.134, on 24 Mar 2017 at 08:43:04, subject to the Cambridge Core terms of use, available at
8Altrecht Psychiatric Institute, Utrecht, The Netherlands
9Department of Psychosis Research, Parnassia Psychiatric
Institute, The Hague, The Netherlands
*Address for correspondence: B. van Oosterhout, GGzE,




Downloaded from https:/www.cambridge.org/core. IP address: 145.97.142.134, on 24 Mar 2017 at 08:43:04, subject to the Cambridge Core terms of use, available at
